The Charles Schwab Corporation
SCHWThe Charles Schwab Corporation's earnings have outrun its stock. EPS grew +55.5% in a year against a +11.5% price move.
The sharpest disagreement: annual EPS moved +55.5% against a +11.5% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (12 weeks in) while the P/BV sits at the 86th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +35.4% year on year, with the the net margin at 37.9%. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
The Charles Schwab Corporation trades at $105, in a confirmed uptrend and 12 weeks into that stage. That is +7.3% against its own 200-day average. It sits at 71% of a 52-week range of $87 to $112. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 10 straight weeks.
Today the stock is in a confirmed uptrend — week 12 of stage 2. At $105 it trades +7.3% versus its 200-day average and sits at 71% of its 52-week range ($87–$112).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +309% while the S&P 500 moved +255% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 10 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each $1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.
The Charles Schwab Corporation trades at 4.2× P/BV, at the pricey end of its own range (86th percentile). Its long-run median P/BV is 3.8×, measured across 5.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/BV of 4.2× is at the pricey end of its own range (86th percentile), against a long-run median of 3.8× measured over 5.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year book value grew while the price moved +11.5% — the price ran ahead of the book, pushing the multiple up its own range.
The price move, decomposed: over 5y, of the +8.3%/yr price move, ~−3.5%/yr came from book-value growth and ~+11.8 pp from the multiple (expanding). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the book-value line underneath it, not the multiple.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
The Charles Schwab Corporation reads as improving on its fundamental arc. Improving — profit growth bottomed 8 quarters ago at −31.1% and has held its recovery at +43.1%, ROE lifting at 19.4%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +22.0% | +4.8% | — | — |
| Profit | +53.6% | +8.3% | — | — |
| EPS | +55.5% | +9.9% | — | — |
| Stock price | +11.5% | +21.8% | +8.3% | +13.2% |
4-Factor Sector Score
70.2/100 — rank 1 of 27 in Capital Markets · 80% evidence confidence
The Charles Schwab Corporation scores 70.2 out of 100 against the 27 companies it is compared with in Capital Markets, ranking 1. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
The four contributions add to the total exactly: 24.4 + 18.8 + 12.6 + 14.4 = 70.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.
Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fees from its businesses.
The Charles Schwab Corporation reported $7.1 B of income in the Jun 26 quarter, +20.9% year on year. That is the 9th straight quarter of year-on-year growth. Over 4 years it has compounded at 6.6% a year. The last full year, FY25, came in at $23.9 B. The last four reported quarters add to $26.0 B.
FY25 revenue came in at $23.9 B (+22.0% on the year), capping 4 years at 6.6% compound. The latest quarter (Jun 26) printed $7.1 B, +20.9% year on year — the 9th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +20.5% growth against the decade's 6.6% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +20.3% over the last 4 quarters against +18.3%/yr over the last 8 — stabilising; TTM profit +43.1% vs +48.5%/yr — rolling over.
Net margin Net margin — what the bank keeps of every $100 of revenue after every cost, provision and tax. With big fee businesses in the mix, it is the cleanest margin we can read for this bank.
The Charles Schwab Corporation's net margin is 37.9% in the Jun 26 quarter, +4.1 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the net margin has ranged 24.6% to 35.2%. The current quarter is running above every full year in that window.
The latest quarter's net margin is 37.9%, +4.1 pp against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 24.6%–35.2%, and FY25's 35.2% is the top of that band — a record year.
Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
The Charles Schwab Corporation earned $2.7 B of net profit in the Jun 26 quarter, +35.4% year on year. It is the 9th consecutive quarter of growth. Full-year FY25 profit was $8.4 B. The 4-year compound rate is 12.0%. That is 37.9% of the quarter's revenue. The same quarter a year earlier earned $2.0 B.
Jun 26 profit was $2.7 B, +35.4% year on year — the 9th consecutive quarter of growth. On the full year, FY25 printed $8.4 B (+53.6%), and the 4-year compound rate is 12.0%.
Why profit moved: revenue contributed +20.9% and the margin +4.1 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +45.5% vs revenue +20.5%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.
Loan-book quality history is not available for The Charles Schwab Corporation, so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.
We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.
Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.
The loan book We read the loan book through revenue — when the book and the businesses grow, revenue grows with them. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.
The Charles Schwab Corporation's revenue grew +22.0% in FY25 to $23.9 B, so the book is growing. The latest quarter ran +20.9% year on year. The net margin on that income is 37.9%, +4.1 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.
FY25 revenue was $23.9 B, +22.0% on the year, and the latest quarter ran +20.9% year on year. The net margin on that revenue is 37.9% this quarter (+4.1 pp YoY) — growth with a widening margin on it.
The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — with quarterly loan-quality numbers missing here, revenue growth and margin are the two we watch.
Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.
The Charles Schwab Corporation earns a return on equity of 17% in FY25. Its trough over the ladder below was 10% in FY21. On the asset side every $100 of the balance sheet earned about $2.07, which is the return before leverage is applied.
FY25 ROE came in at 17%, recovered from a FY21 trough of 10%. On assets, the latest reading is about 2.07% — every $100 the bank deploys earns roughly $2.07 a year. That clears the bar a bank must beat for its book value to compound.
Why ROE moved: profit compounded 12.0% a year over 4 years while the equity base grew more slowly — earnings recovering faster than book value builds is what lifts ROE off a trough.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
The Charles Schwab Corporation paid $1.18 per share over the last four reported quarters. The most recent declaration was $0.32 for Jun 26. Against the current price of $105 that is a trailing yield of 1.12%, measured on dividends already paid rather than on a forecast.
The Charles Schwab Corporation paid $1.18 per share across the last four reported quarters, most recently $0.32 for Jun 26. Against the current price of $105 the trailing twelve months work out to 1.12% — trailing dividends measured against today's price, not a forward estimate.
Debt
For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.
A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
0.0% of The Charles Schwab Corporation's tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 0.0 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 0.0% of the float is sold short, and at typical trading volumes it would take about 0.0 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
The Charles Schwab Corporation: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.
The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1The Charles Schwab Corporationthis pageSCHW | 70.2/100Favorable setup80% evidence | BREAKING OUT | 24.4/35 Income 20.3% · PAT 43.2% 81% evidence | 18.8/25 ROA 2% · ROE 20.1% · GNPA — 68% evidence | 12.6/20 P/BV 3.2× · P/BV÷ROE 0.16 70% evidence | 14.4/20 RS sector 0.3% · RS bench 1.3% · 1Y 11.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 18.8 + 12.6 + 14.4 = 70.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Marex Group LimitedMRX | 62.8/100Mixed-positive evidence76% evidence | LEADER | 23.3/35 Income 32.6% · PAT 40.9% 71% evidence | 12.0/25 ROA 0.6% · ROE 9.4% · GNPA — 68% evidence | 9.1/20 P/BV 2.56× · P/BV÷ROE 0.27 70% evidence | 18.4/20 RS sector 40.6% · RS bench 41.5% · 1Y 120.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 23.3 + 12 + 9.1 + 18.4 = 62.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Morgan StanleyMS | 62.7/100Mixed-positive evidence80% evidence | ASLEEP | 19.8/35 Income 18.6% · PAT 36.8% 81% evidence | 17.6/25 ROA 1.5% · ROE 19.8% · GNPA — 68% evidence | 13.8/20 P/BV 2.81× · P/BV÷ROE 0.14 70% evidence | 11.5/20 RS sector 1.1% · RS bench 1.9% · 1Y 26.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 17.6 + 13.8 + 11.5 = 62.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Virtu Financial, Inc.VIRT | 58.4/100Mixed-positive evidence60% evidence | FADING | 14.1/35 Income — · PAT — 26% evidence | 15.9/25 ROA 1.3% · ROE 14.4% · GNPA — 68% evidence | 13.5/20 P/BV 2.21× · P/BV÷ROE 0.15 70% evidence | 14.9/20 RS sector 16.2% · RS bench 17.1% · 1Y 61.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 15.9 + 13.5 + 14.9 = 58.4 · Decision use: Price leads the evidence: RS versus the benchmark is 17.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 5The Goldman Sachs Group, Inc.GS | 57.6/100Mixed-positive evidence80% evidence | ASLEEP | 20.1/35 Income 23.3% · PAT 35.8% 81% evidence | 16.3/25 ROA 1.2% · ROE 18.1% · GNPA — 68% evidence | 14.4/20 P/BV 2.51× · P/BV÷ROE 0.14 70% evidence | 6.8/20 RS sector -5.3% · RS bench -4.4% · 1Y 16.5%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 16.3 + 14.4 + 6.8 = 57.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6StoneX Group Inc.SNEX | 57.5/100Mixed-positive evidence62% evidence | ASLEEP | 23.8/35 Income 38% · PAT 56.1% 55% evidence | 12.8/25 ROA — · ROE 7.6% · GNPA — 34% evidence | 7.7/20 P/BV 2.36× · P/BV÷ROE 0.31 70% evidence | 13.2/20 RS sector 7.2% · RS bench 7.9% · 1Y 64%3 of 12 weeks ahead 100% evidence |
| Exact sum: 23.8 + 12.8 + 7.7 + 13.2 = 57.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Piper Sandler CompaniesPIPR | 51.2/100Mixed-positive evidence60% evidence | ASLEEP | 21.7/35 Income — · PAT — 26% evidence | 17.9/25 ROA 7.2% · ROE 10% · GNPA — 68% evidence | 7.0/20 P/BV 3.87× · P/BV÷ROE 0.39 70% evidence | 4.6/20 RS sector -18.3% · RS bench -17.5% · 1Y -22.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 17.9 + 7 + 4.6 = 51.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Tradeweb Markets Inc.TW | 50.3/100Mixed-positive evidence80% evidence | TURNING | 22.3/35 Income 14.1% · PAT 60.6% 81% evidence | 13.8/25 ROA 2.3% · ROE 2.9% · GNPA — 68% evidence | 4.8/20 P/BV 3.17× · P/BV÷ROE 1.09 70% evidence | 9.4/20 RS sector -12.9% · RS bench -12% · 1Y -8.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 13.8 + 4.8 + 9.4 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9PJT Partners Inc.PJT | 49.4/100Mixed-negative evidence60% evidence | ASLEEP | 20.0/35 Income — · PAT — 26% evidence | 17.3/25 ROA 5% · ROE 8.9% · GNPA — 68% evidence | 3.5/20 P/BV 12.38× · P/BV÷ROE 1.39 70% evidence | 8.6/20 RS sector -13.2% · RS bench -12.5% · 1Y -18.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 17.3 + 3.5 + 8.6 = 49.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 10BGC Group, Inc.BGC | 49.0/100Mixed-negative evidence60% evidence | TURNING | 16.8/35 Income — · PAT — 26% evidence | 8.8/25 ROA 0.4% · ROE 5.8% · GNPA — 68% evidence | 5.5/20 P/BV 4.63× · P/BV÷ROE 0.8 70% evidence | 17.9/20 RS sector 11.3% · RS bench 12.2% · 1Y 24.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 8.8 + 5.5 + 17.9 = 49 · Decision use: Price leads the evidence: RS versus the benchmark is 12.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 11Figure Technology Solutions, Inc.FIGR | 48.3/100Mixed-negative evidence61% evidence | BREAKING OUT | 24.1/35 Income 67.8% · PAT 100% 45% evidence | 13.8/25 ROA 2.4% · ROE 5.4% · GNPA — 68% evidence | 4.9/20 P/BV 5.76× · P/BV÷ROE 1.07 70% evidence | 5.5/20 RS sector -17.2% · RS bench -16.6% · 1Y -26%4 of 12 weeks ahead 70% evidence |
| Exact sum: 24.1 + 13.8 + 4.9 + 5.5 = 48.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -17.2% and the one-year return is -26%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12MarketAxess Holdings Inc.MKTX | 47.0/100Mixed-negative evidence60% evidence | BREAKING OUT | 15.1/35 Income — · PAT — 26% evidence | 14.8/25 ROA 3.1% · ROE 5.1% · GNPA — 68% evidence | 6.0/20 P/BV 3.26× · P/BV÷ROE 0.64 70% evidence | 11.1/20 RS sector -5.9% · RS bench -4.8% · 1Y -8.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 14.8 + 6 + 11.1 = 47 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Evercore Inc.EVR | 46.2/100Mixed-negative evidence60% evidence | ASLEEP | 21.0/35 Income — · PAT — 26% evidence | 18.5/25 ROA 6.1% · ROE 11.1% · GNPA — 68% evidence | 5.8/20 P/BV 6.48× · P/BV÷ROE 0.58 70% evidence | 0.9/20 RS sector -25.4% · RS bench -24.7% · 1Y -26.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 18.5 + 5.8 + 0.9 = 46.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 14Interactive Brokers Group, Inc.IBKR | 45.9/100Mixed-negative evidence80% evidence | FADING | 17.0/35 Income 21.3% · PAT 29.8% 81% evidence | 10.4/25 ROA 0.6% · ROE 6.6% · GNPA — 68% evidence | 5.0/20 P/BV 6.64× · P/BV÷ROE 1.01 70% evidence | 13.5/20 RS sector 4.6% · RS bench 5.4% · 1Y 33.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 10.4 + 5 + 13.5 = 45.9 · Decision use: Price leads the evidence: RS versus the benchmark is 5.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15LPL Financial Holdings Inc.LPLA | 45.9/100Mixed-negative evidence80% evidence | BREAKING OUT | 14.0/35 Income 38.8% · PAT -10% 81% evidence | 15.1/25 ROA 2.4% · ROE 7% · GNPA — 68% evidence | 6.4/20 P/BV 3.87× · P/BV÷ROE 0.55 70% evidence | 10.4/20 RS sector -7.5% · RS bench -6.6% · 1Y -0.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 14 + 15.1 + 6.4 + 10.4 = 45.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Stifel Financial Corp.SF | 44.8/100Mixed-negative evidence60% evidence | FADING | 16.4/35 Income — · PAT — 26% evidence | 8.3/25 ROA -2% · ROE 8.1% · GNPA — 68% evidence | 10.5/20 P/BV 1.9× · P/BV÷ROE 0.23 70% evidence | 9.6/20 RS sector -10.7% · RS bench -9.8% · 1Y -1.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 8.3 + 10.5 + 9.6 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Moelis & CompanyMC | 44.2/100Mixed-negative evidence60% evidence | ASLEEP | 17.6/35 Income — · PAT — 26% evidence | 16.3/25 ROA 3.9% · ROE 8.9% · GNPA — 68% evidence | 4.3/20 P/BV 9.58× · P/BV÷ROE 1.08 70% evidence | 6.0/20 RS sector -17.1% · RS bench -16.4% · 1Y -23.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 16.3 + 4.3 + 6 = 44.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 18Robinhood Markets, Inc.HOOD | 41.6/100Mixed-negative evidence80% evidence | ASLEEP | 17.5/35 Income 38.3% · PAT 16.3% 81% evidence | 10.3/25 ROA 1% · ROE 6.5% · GNPA — 68% evidence | 3.4/20 P/BV 9.51× · P/BV÷ROE 1.46 70% evidence | 10.4/20 RS sector -4.9% · RS bench -4.1% · 1Y -16.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 10.3 + 3.4 + 10.4 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Riot Platforms, Inc.RIOT | 40.7/100Thin evidence · provisional55% evidence | ASLEEP | 15.6/35 Income 42.3% · PAT — 45% evidence | 4.5/25 ROA -14% · ROE -18.7% · GNPA — 68% evidence | 9.8/20 P/BV 1.96× · P/BV÷ROE — 10% evidence | 10.8/20 RS sector 2% · RS bench 2.5% · 1Y 16.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 4.5 + 9.8 + 10.8 = 40.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Galaxy Digital Inc.GLXY | 39.6/100Thin evidence · provisional53% evidence | ASLEEP | 22.6/35 Income 25.5% · PAT — 45% evidence | 5.5/25 ROA -2.8% · ROE -10.6% · GNPA — 68% evidence | 10.0/20 P/BV — · P/BV÷ROE — 0% evidence | 1.5/20 RS sector -21.6% · RS bench -21.2% · 1Y -32.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 5.5 + 10 + 1.5 = 39.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Jefferies Financial Group Inc.JEF | 39.0/100Mixed-negative evidence80% evidence | ASLEEP | 21.4/35 Income 21.4% · PAT 39.5% 81% evidence | 8.3/25 ROA 0.3% · ROE 2.4% · GNPA — 68% evidence | 6.7/20 P/BV 1.01× · P/BV÷ROE 0.42 70% evidence | 2.6/20 RS sector -18.4% · RS bench -17.7% · 1Y -31.9%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 8.3 + 6.7 + 2.6 = 39 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Houlihan Lokey, Inc.HLI | 37.3/100Mixed-negative evidence60% evidence | BASING | 14.3/35 Income — · PAT — 26% evidence | 13.7/25 ROA 2% · ROE 3.5% · GNPA — 68% evidence | 4.4/20 P/BV 4.11× · P/BV÷ROE 1.17 70% evidence | 4.9/20 RS sector -24.4% · RS bench -23.6% · 1Y -37.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.3 + 13.7 + 4.4 + 4.9 = 37.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23TeraWulf Inc.WULF | 37.0/100Thin evidence · provisional55% evidence | ASLEEP | 19.3/35 Income 28% · PAT — 45% evidence | 4.4/25 ROA -4.1% · ROE -897.3% · GNPA — 68% evidence | 9.8/20 P/BV -77.86× · P/BV÷ROE — 10% evidence | 3.5/20 RS sector -14.6% · RS bench -14% · 1Y 40.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 4.4 + 9.8 + 3.5 = 37 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24IREN LimitedIREN | 34.4/100Thin evidence · provisional55% evidence | ASLEEP | 16.4/35 Income 100% · PAT — 45% evidence | 4.8/25 ROA -4.9% · ROE -12.1% · GNPA — 68% evidence | 9.6/20 P/BV 4.39× · P/BV÷ROE — 10% evidence | 3.6/20 RS sector -15.4% · RS bench -14.8% · 1Y 10.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 4.8 + 9.6 + 3.6 = 34.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Circle Internet Group, Inc.CRCL | 30.4/100Adverse evidence76% evidence | BASING | 12.8/35 Income 51.4% · PAT -146.2% 71% evidence | 6.6/25 ROA 0.1% · ROE 2.1% · GNPA — 68% evidence | 3.2/20 P/BV 6.89× · P/BV÷ROE 3.28 70% evidence | 7.8/20 RS sector -18% · RS bench -17.3% · 1Y -44.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 6.6 + 3.2 + 7.8 = 30.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Hut 8 Corp.HUT | 51.8/100Thin evidence · provisional41% evidence | ASLEEP | 19.5/35 Income 100% · PAT — 29% evidence | 8.7/25 ROA — · ROE -18.9% · GNPA — 34% evidence | 9.8/20 P/BV 3.83× · P/BV÷ROE — 10% evidence | 13.8/20 RS sector 20.6% · RS bench 21.2% · 1Y 147.8%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 8.7 + 9.8 + 13.8 = 51.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Bitmine Immersion Technologies, Inc.BMNR | 39.3/100Thin evidence · provisional48% evidence | BREAKING OUT | 16.2/35 Income — · PAT — 26% evidence | 6.2/25 ROA 0.2% · ROE -1.4% · GNPA — 68% evidence | 9.8/20 P/BV 0.96× · P/BV÷ROE — 10% evidence | 7.1/20 RS sector -19.9% · RS bench -19.3% · 1Y -62.8%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 6.2 + 9.8 + 7.1 = 39.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is The Charles Schwab Corporation's stock price today?
The Charles Schwab Corporation trades at $105, +11.5% over the past year. The company is valued at $182 B. The stock sits at 71% of its 52-week range of $87–$112, +7.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 12 weeks in. — as of 17 September 2026.
What were The Charles Schwab Corporation's latest quarterly results?
The Charles Schwab Corporation reported total income of $7.1 B and net profit of $2.7 B for the Jun 26 quarter. Income rose 20.9% and profit rose 35.4% year on year. Earnings per share were $1.54. The net margin was 37.9%, 4.1 pp higher than a year earlier. — as of 17 September 2026.
What is The Charles Schwab Corporation's revenue?
The Charles Schwab Corporation reported revenue of $7.1 B in the Jun 26 quarter, +20.9% year on year. For the full FY25 fiscal year, revenue was $23.9 B (+22.0%). Over the last 4 years revenue compounded at 6.6% a year. — as of 17 September 2026.
What is The Charles Schwab Corporation's profit?
The Charles Schwab Corporation earned $2.7 B of net profit in the Jun 26 quarter, +35.4% year on year — the 9th straight quarter of growth. Full-year FY25 profit was $8.4 B. The net margin ran 37.9% in the latest quarter. — as of 17 September 2026.
What is The Charles Schwab Corporation's market cap?
The Charles Schwab Corporation's market capitalisation is $182 B at a stock price of $105. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is The Charles Schwab Corporation's P/BV ratio?
The Charles Schwab Corporation trades at a P/BV of 4.2×, at the 86th percentile of its own 5-year range, against a long-run median of 3.8×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does The Charles Schwab Corporation pay a dividend?
Yes — The Charles Schwab Corporation declared $0.32 per share for Jun 26, and $1.18 per share across the last four reported quarters. — as of 17 September 2026.
What is The Charles Schwab Corporation's dividend per share?
The Charles Schwab Corporation's most recently declared dividend is $0.32 per share for Jun 26, giving $1.18 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is The Charles Schwab Corporation's dividend yield?
The Charles Schwab Corporation's trailing dividend yield is 1.12%: $1.18 declared per share across the last four reported quarters, against a share price of $105. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
Is The Charles Schwab Corporation overvalued?
On its own history, The Charles Schwab Corporation looks expensive: its P/BV of 4.2× sits at the 86th percentile of its 5-year range (long-run median 3.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: the net margin is the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 17 September 2026.
Is The Charles Schwab Corporation growing?
Yes — The Charles Schwab Corporation is growing: latest-quarter revenue +20.9% year on year, profit +35.4%, and the net margin +4.1 pp at 37.9%. The 4-year compound rates are 6.6% (revenue) and 12.0% (profit). The earnings engine currently reads: improving — as of 17 September 2026.
How is The Charles Schwab Corporation performing?
The Charles Schwab Corporation is in a confirmed uptrend, 12 weeks in. Its latest quarter's income rose 20.9% and profit rose 35.4% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 10 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is The Charles Schwab Corporation in?
Improving — profit growth bottomed 8 quarters ago at −31.1% and has held its recovery at +43.1%, ROE lifting at 19.4%. The read comes from the last 12 quarters of growth (revenue growth +20.3% latest, profit growth +43.1% latest, eps growth +47.8% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is The Charles Schwab Corporation in an uptrend?
Yes — the price is in a confirmed uptrend (week 12 of stage 2), trading +7.3% versus its 200-day average and at 71% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is The Charles Schwab Corporation beating the market?
On recent form, yes — The Charles Schwab Corporation has been ahead of the S&P 500 on a trailing-13-week view for 10 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +309% against the S&P 500's +255% — ahead of the index over the full window. — as of 17 September 2026.
Will The Charles Schwab Corporation's stock price go up?
This page publishes no price forecast for The Charles Schwab Corporation. What it measures instead: the stock price is $105, the price is in a confirmed uptrend 12 weeks in. Its P/BV of 4.2× sits at the 86th percentile of its own 5-year range. — as of 17 September 2026.
Is the market betting against The Charles Schwab Corporation?
No — short interest is 0.0% of The Charles Schwab Corporation's tradable float, about 0.0 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Where is The Charles Schwab Corporation in its business cycle?
The Charles Schwab Corporation's FY25 net margin was 35.2%, against a 5-year band of 24.6%–35.2%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 37.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the The Charles Schwab Corporation story?
The sharpest disagreement: annual EPS moved +55.5% against a +11.5% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is The Charles Schwab Corporation a stock worth studying right now?
This is not investment advice. The machine read: The Charles Schwab Corporation's earnings have outrun its stock. EPS grew +55.5% in a year against a +11.5% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!